Amprenavir Complexes with HIV-1 Protease and Its Drug-resistant Mutants Altering Hydrophobic Clusters

Overview

Journal FEBS J

Specialty Biochemistry

Date 2010 Aug 11

PMID 20695887

Citations 63

Authors

Chen-Hsiang Shen

Yuan-Fang Wang

Andrey Y Kovalevsky

Robert W Harrison

Irene T Weber

Affiliations

Soon will be listed here.

Abstract

The structural and kinetic effects of amprenavir (APV), a clinical HIV protease (PR) inhibitor, were analyzed with wild-type enzyme and mutants with single substitutions of V32I, I50V, I54V, I54M, I84V and L90M that are common in drug resistance. Crystal structures of the APV complexes at resolutions of 1.02-1.85 Å reveal the structural changes due to the mutations. Substitution of the larger side chains in PR(V32I) , PR(I54M) and PR(L90M) resulted in the formation of new hydrophobic contacts with flap residues, residues 79 and 80, and Asp25, respectively. Mutation to smaller side chains eliminated hydrophobic interactions in the PR(I50V) and PR(I54V) structures. The PR(I84V)-APV complex had lost hydrophobic contacts with APV, the PR(V32I)-APV complex showed increased hydrophobic contacts within the hydrophobic cluster and the PR(I50V) complex had weaker polar and hydrophobic interactions with APV. The observed structural changes in PR(I84V)-APV, PR(V32I)-APV and PR(I50V)-APV were related to their reduced inhibition by APV of six-, 10- and 30-fold, respectively, relative to wild-type PR. The APV complexes were compared with the corresponding saquinavir complexes. The PR dimers had distinct rearrangements of the flaps and 80's loops that adapt to the different P1' groups of the inhibitors, while maintaining contacts within the hydrophobic cluster. These small changes in the loops and weak internal interactions produce the different patterns of resistant mutations for the two drugs.

Citing Articles

Identification of steroidal cardenolides from Calotropis procera as novel HIV-1 PR inhibitors: A molecular docking & molecular dynamics simulation study.

Swapna K, Srujana M, Mamidala E Indian J Med Res. 2024; 160(1):78-86.

PMID: 39382500 PMC: 11463882. DOI: 10.25259/IJMR_2115_23.

Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide.

Jang J, Kim J, Lee T Genes Genomics. 2024; 46(12):1345-1361.

PMID: 39271535 DOI: 10.1007/s13258-024-01565-z.

Enthalpic Classification of Water Molecules in Target-Ligand Binding.

Szel V, Zsido B, Hetenyi C J Chem Inf Model. 2024; 64(16):6583-6595.

PMID: 39135312 PMC: 11351019. DOI: 10.1021/acs.jcim.4c00794.

Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.

Manna S, Das K, Santra S, Nosova E, Zyryanov G, Halder S Viruses. 2023; 15(9).

PMID: 37766233 PMC: 10536032. DOI: 10.3390/v15091826.

Chemical features and machine learning assisted predictions of protein-ligand short hydrogen bonds.

Zhou S, Liu Y, Wang S, Wang L Sci Rep. 2023; 13(1):13741.

PMID: 37612311 PMC: 10447522. DOI: 10.1038/s41598-023-40614-7.

References

Wu T, Schiffer C, Gonzales M, Taylor J, Kantor R, Chou S . Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol. 2003; 77(8):4836-47. PMC: 152121. DOI: 10.1128/jvi.77.8.4836-4847.2003. View

Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T . Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003; 47(10):3123-9. PMC: 201142. DOI: 10.1128/AAC.47.10.3123-3129.2003. View

Mahalingam B, Louis J, Hung J, Harrison R, Weber I . Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins. 2001; 43(4):455-64. DOI: 10.1002/prot.1057. View

Randolph J, Degoey D . Peptidomimetic inhibitors of HIV protease. Curr Top Med Chem. 2004; 4(10):1079-95. DOI: 10.2174/1568026043388330. View

Gustchina A, Sansom C, Prevost M, RICHELLE J, Wodak S, Wlodawer A . Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures. Protein Eng. 1994; 7(3):309-17. DOI: 10.1093/protein/7.3.309. View

Short 3rd G, Laikhter A, Lodder M, Shayo Y, Arslan T, Hecht S . Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues. Biochemistry. 2000; 39(30):8768-81. DOI: 10.1021/bi000214t. View

Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

Hoffman N, Schiffer C, Swanstrom R . Covariation of amino acid positions in HIV-1 protease. Virology. 2003; 314(2):536-48. DOI: 10.1016/s0042-6822(03)00484-7. View

Louis J, Ishima R, Torchia D, Weber I . HIV-1 protease: structure, dynamics, and inhibition. Adv Pharmacol. 2007; 55:261-98. DOI: 10.1016/S1054-3589(07)55008-8. View

10.

McCoy A, Grosse-Kunstleve R, Storoni L, Read R . Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 4):458-64. DOI: 10.1107/S0907444905001617. View

11.

Wang Y, Tie Y, Boross P, Tozser J, Ghosh A, Harrison R . Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J Med Chem. 2007; 50(18):4509-15. PMC: 2751596. DOI: 10.1021/jm070482q. View

12.

Stebbins J, Towler E, Tennant M, Deckman I, Debouck C . The 80's loop (residues 78 to 85) is important for the differential activity of retroviral proteases. J Mol Biol. 1997; 267(3):467-75. DOI: 10.1006/jmbi.1997.0891. View

13.

Williams , Sinko . Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev. 2000; 39(1-3):211-238. DOI: 10.1016/s0169-409x(99)00027-7. View

14.

Cigler P, Kozisek M, rezacova P, Brynda J, Otwinowski Z, Pokorna J . From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc Natl Acad Sci U S A. 2005; 102(43):15394-9. PMC: 1255736. DOI: 10.1073/pnas.0507577102. View

15.

Kovalevsky A, Liu F, Leshchenko S, Ghosh A, Louis J, Harrison R . Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol. 2006; 363(1):161-73. PMC: 1781337. DOI: 10.1016/j.jmb.2006.08.007. View

16.

Condra J, Schleif W, Blahy O, Gabryelski L, Graham D, Quintero J . In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995; 374(6522):569-71. DOI: 10.1038/374569a0. View

17.

Sayer J, Liu F, Ishima R, Weber I, Louis J . Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem. 2008; 283(19):13459-70. PMC: 2442353. DOI: 10.1074/jbc.M708506200. View

18.

Murshudov G, Vagin A, Dodson E . Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997; 53(Pt 3):240-55. DOI: 10.1107/S0907444996012255. View

19.

Pazhanisamy S, Stuver C, Cullinan A, Margolin N, Rao B, Livingston D . Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J Biol Chem. 1996; 271(30):17979-85. DOI: 10.1074/jbc.271.30.17979. View

20.

Vaguine A, RICHELLE J, Wodak S . SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr D Biol Crystallogr. 1999; 55(Pt 1):191-205. DOI: 10.1107/S0907444998006684. View